Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 5

Sustained effects of integrated COPD management on health status and exercise capacity in primary care patients

Authors Annemarije L Kruis, Joan van Adrichem, Magda R Erkelens, et al

Published 25 November 2010 Volume 2010:5 Pages 407—413

DOI https://doi.org/10.2147/COPD.S9654

Review by Single-blind

Peer reviewer comments 3

Annemarije L Kruis1, Joan van Adrichem2, Magda R Erkelens2, Huub Scheepers3, Hans in ’t Veen4, Jean WM Muris5, Niels H Chavannes1
1Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, 2Physiotherapy Center De Beweging, Rotterdam, 3Well-being Medical Center, Bocholtz-Simpelveld, 4Department of Pulmonary Diseases, Sint Franciscus Gasthuis, Rotterdam, 5Department of General Practice, Maastricht University Medical Center, The Netherlands

Background: Chronic obstructive pulmonary disease (COPD) constitutes a growing health care problem worldwide. Integrated disease management (IDM) of mild to moderate COPD patients has been demonstrated to improve exercise capacity and health status after one year, but long-term results are currently lacking in primary care.
Methods: Long-term data from the Bocholtz study, a controlled clinical trial comparing the effects of IDM versus usual care on health status in 106 primary care COPD patients during 24 months of follow-up, were analyzed using the Clinical COPD Questionnaire (CCQ). In addition, the Kroonluchter IDM implementation program has treated 216 primary care patients with mild to moderate COPD since 2006. Longitudinal six-minute walking distance (6MWD) results for patients reaching 24 months of follow-up were analyzed using paired-sample t-tests. In prespecified subgroup analyses, the differential effects of baseline CCQ score, Medical Research Council (MRC) dyspnea score, and 6MWD were investigated.
Results: In the Bocholtz study, subjects were of mean age 64 years, with an average postbronchodilator forced expiratory volume in one second (FEV1) of 63% predicted and an FEV1/forced vital capacity (FVC) ratio of 0.56. No significant differences existed between groups at baseline. CCQ improved significantly and in a clinically relevant manner by 0.4 points over 24 months; effect sizes were doubled in patients with CCQ > 1 at baseline and tripled in patients with MRC dyspnea score > 2. In the Kroonluchter cohort, 56 subjects completed follow-up, were of mean age 69 years, with an FEV1/FVC ratio of 0.59, while their postbronchodilator FEV1 of 65% predicted was somewhat lower than in the total group. 6MWD improved significantly and in a clinically relevant manner up to 93 m at 12 months and was sustained at 83 m over 24 months; this effect occurred faster in patients with MRC dyspnea score > 2. In patients with baseline 6MWD < 400 m the improvement remained >100 m at 24 months.
Conclusion: In this study, IDM improved and sustained health status and exercise capacity in primary care COPD patients during two years of follow-up. Improvements in health status are consistently higher in patients with CCQ > 1 at baseline, being strongest in patients with baseline MRC dyspnea score >2. Improvements in exercise capacity remain highest in patients with 6MWD < 400 m at baseline and seem to occur earlier in patients with MRC dyspnea score >2.

Keywords: chronic obstructive pulmonary disease, disease management, integrated care, pulmonary rehabilitation, primary care

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Predictive value and utility of oral steroid testing for treatment of COPD in primary care: the COOPT study

Niels H Chavannes, Tjard RJ Schermer, Emiel FM Wouters, et al

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:431-436

Published Date: 19 November 2009

Readers of this article also read:

Safety of indacaterol in the treatment of patients with COPD

Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, Kramer B

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:477-492

Published Date: 22 September 2011

Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease

Heike Rau-Berger, Harald Mitfessel, Thomas Glaab

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:367-373

Published Date: 10 October 2010

Interleukin-6 and airflow limitation in chemical warfare patients with chronic obstructive pulmonary disease

Davood Attaran, Shahrzad M Lari, Mohammad Towhidi, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:335-340

Published Date: 30 September 2010

Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone

Beatrix Balint, Henrik Watz, Carolynn Amos, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:311-318

Published Date: 6 September 2010

Influencing the decline of lung function in COPD: use of pharmacotherapy

Ekaterina S Gladysheva, Atul Malhotra, Robert L Owens

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:153-164

Published Date: 17 May 2010